NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’ LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD,...

NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100® Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...

Brain Tumor Treatment Market is expected to accumulate a Value of US$ 5,904.82 Million by registering a CAGR of 7.2% | Future Market Insights, Inc. NEWARK, Del, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The global brain tumor treatment market is anticipated to showcase an opulent growth opportunity over the estimation period from 2022 to 2032 with a...

Brain Cancer Diagnostics Market Revenue to Cross $7.37 Bn Globally, by 2028 at 28.5.% CAGR - Exclusive Report by The Insight Partners New York, July 15, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Brain Cancer Diagnostic Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...

First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a...